X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Leap intends to use the net proceeds from the financing to fund the continued development of its lead monoclonal antibody program, DKN-01 for the treatment of Colorectal Cancer.
Lead Product(s): Sirexatamab,Fluorouracil,Irinotecan Hydrochloride
Therapeutic Area: Oncology Product Name: DKN-01
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Gilead Sciences
Deal Size: $40.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement April 11, 2024
Details:
DKN-01, is an anti-Dickkopf-1 (DKK1) antibody and in combination with standard of care bevacizumab and chemotherapy as a second-line treatment for patients with advanced CRC.
Lead Product(s): Sirexatamab,Bevacizumab,Irinotecan Hydrochloride
Therapeutic Area: Oncology Product Name: DKN-01
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 12, 2023
Details:
DKN-01 is a humanized monoclonal antibody that binds to and blocks the activity of the Dickkopf-1 (DKK1) protein. DKK1 has an important role in mediating an immune suppressive tumor microenvironment and in promoting tumor proliferation, metastasis, and angiogenesis.
Lead Product(s): DKN-01,Bevacizumab,Irinotecan Hydrochloride
Therapeutic Area: Oncology Product Name: DKN-01
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 12, 2023
Details:
FL-301 is a fully human monoclonal antibody that binds to and blocks Claudin18.2. Claudin18.2 regulates barrier properties and contributes to cell-to-cell adhesion.
Lead Product(s): FL-301
Therapeutic Area: Oncology Product Name: FL-301
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Leap Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition January 17, 2023
Details:
DKN-01 is a humanized monoclonal antibody that binds to and blocks the activity of the Dickkopf-1 (DKK1) protein. DKK1 modulates the Wnt/Beta-catenin and PI3kinase/AKT signaling pathways and has an important role in promoting tumor proliferation, metastasis, angiogenesis.
Lead Product(s): DKN-01,Bevacizumab,Irinotecan Hydrochloride
Therapeutic Area: Oncology Product Name: DKN-01
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 17, 2022
Details:
No DLTs were observed at DKN-01 300mg or 600mg dose levels as monotherapy or in combination with docetaxel, and no treatment-related adverse events occurred in either cohort.
Lead Product(s): DKN-01,Docetaxel
Therapeutic Area: Oncology Product Name: DKN-01
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
DKN-01 plus tislelizumab and chemotherapy demonstrated compelling activity in first-line patients with gastric or gastroesophageal junction cancer. DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein.
Lead Product(s): DKN-01,Tislelizumab
Therapeutic Area: Oncology Product Name: DKN-01
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 16, 2021
Details:
The DisTinGuish study is a Phase 2a, non-randomized, open-label, multicenter study of DKN-01 in combination with tislelizumab, as first-line or second-line therapy in adult patients with inoperable, locally advanced gastric or gastroesophageal junction cancer adenocarcinoma.
Lead Product(s): DKN-01,Tislelizumab
Therapeutic Area: Oncology Product Name: DKN-01
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 26, 2021
Details:
The DisTinGuish trial is a Phase 2a, nonrandomized, open-label, multicenter study of DKN-01 in combination with tislelizumab with or without chemotherapy as first-line or second-line therapy in adult patients with inoperable, locally advanced G/GEJ adenocarcinoma.
Lead Product(s): DKN-01,Tislelizumab
Therapeutic Area: Oncology Product Name: DKN-01
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2021
Details:
The P204 study was a Phase 2 basket study evaluating DKN-01 as a monotherapy or in combination with paclitaxel in groups composed of epithelial endometrial cancer (EEC), epithelial ovarian cancer (EOC), or carcinosarcoma (MMMT) patients.
Lead Product(s): DKN-01
Therapeutic Area: Oncology Product Name: DKN-01
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
